Literature DB >> 8877728

Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy.

M Casaril1, F Capra, G B Gabrielli, A Bassi, S Squarzoni, R Dagradi, E De Maria, R Corrocher.   

Abstract

We investigated the prevalence of mixed cryoglobulinemia (MC) in 100 cases of chronic hepatitis C virus (HCV) infection and the effect of a 6-month treatment with interferon-alpha (IFN-alpha). Cryoglobulins were detected on admission in 36 of 100 patients and appeared during observation in a further 18 cases. Cryocrit ranged from 0.5% to 20%. Patients with MC were older and had a higher incidence of cirrhosis than those without MC. Immunologic characterization of the cryoprecipitate showed the presence of type II in 84% of cases and type III in 16%. The patients received IFN-alpha (6 MU three times per week) for 6 months. Fifty-seven were responders (i.e., reached normal aminotransferase levels), 26 of these relapsed within 2 months after IFN withdrawal, and 30 did not relapse. After IFN-alpha treatment, cryoglobulinemia disappeared in 11 of the 21 evaluable responders, but in none of the 15 nonresponder patients (p < 0.003). The clearance of MC was associated in all cases with clearance of HCV RNA. The delayed appearance of cryoglobulinemia in responders seems to be associated with a higher probability of relapse.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877728     DOI: 10.1089/jir.1996.16.585

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  2 in total

1.  Treatment of hepatitis C cryoglobulinemia: mission and challenges.

Authors:  Zeid Kayali; Douglas R Labrecque; Warren N Schmidt
Journal:  Curr Treat Options Gastroenterol       Date:  2006

Review 2.  Hepatitis C virus-related lymphoproliferative disorders: an overview.

Authors:  Anna-Linda Zignego; Carlo Giannini; Clodoveo Ferri
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.